La cadena de opciones muestra datos clave de las opciones de acciones de Actuate Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Actuate Therapeutics..

Actuate Therapeutics (NASDAQ:ACTU) Bolsa, Cadena de Opciones

Actuate Therapeutics

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics Inc

Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) has outperformed the market over the past 5 years by 9.49% on an annualized basis producing an average annual return of 23.07%. Currently, Watsco has a market capitalization of $20.54 billion. 
Buying $1000 In WSO: If an investor had bought $1000 of WSO stock 5 years ago, it would be worth $2,843.78 today based on a price of $509.72 for WSO at the time of writing.
<h3>Watsco's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734133517_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $1000 Invested In Watsco 5 Years Ago Would Be Worth Today

CKPT

Trading Halt: Halt status updated at 6:40:00 PM ET: Quotation Resumption: News and Resumption Times

Bernie Sanders is <a href="https://www.benzinga.com/personal-finance/24/07/39817447/warren-buffett-says-anyone-who-works-40-hours-a-week-should-live-a-decent-life-heres-what-he-pro">challenging the wealthiest Americans</a> with his call for a 100% tax on income above $1 billion. In a May 2023 interview on HBO's Who's Talking to Chris Wallace?, Sanders explained his stance: "You may disagree with me, but I think people can make it on $999 million. I think that they can survive just fine."
According to a Fortune article, Wallace asked, "Are you basically saying that once you get to $999 million, the government should confiscate all the rest?" Sanders responded with a direct "yeah."
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
This reflects his <a href="https://www.benzinga.com/startups/24/12/42320573/musks-119-billion-wealth-increase-outpaces-dell-and-zuckerberg-but-guess-whos-catching-up">belief that the ultrarich</a> should not exist in a society with such extreme economic inequality. On his official Facebook page in September 2024, Sanders doubled down, saying, "We live in a nation today that has more income and wealth inequality than has ever existed in the history of the United States." He painted a stark picture of the divide, stating that while the billionaire class is "<a href="https://www.benzinga.com/personal-finance/24/11/42217382/bernie-sanders-demands-scrap-the-cap-on-social-security-taxes-its-absurd-a-billionaire-pays-same-amount-as-middle-class-earners">doing phenomenally well</a>," 60% of Americans are "living paycheck to paycheck."
Sanders also addressed critics of his approach, saying, "What I believe is that we got to take on the greed of the billionaire class and say, yes, you know what, guys … you are going to start <a href="https://www.benzinga.com/personal-finance/24/11/42217382/bernie-sanders-demands-scrap-the-cap-on-social-security-taxes-its-absurd-a-billionaire-pays-same-amount-as-middle-class-earners">paying your fair share of taxes.</a>"&nbsp;
His plan doesn't just target billionaires' income – it includes a progressive wealth tax on households worth over $32 million, starting at 1% and climbing to 8% for billionaires. He's also proposed an exit tax of 40–60% on assets for those renouncing U.S. citizenship to avoid taxes.
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Critics argue that Sanders' wealth tax proposal could backfire, especially when fostering innovation and entrepreneurship. The National Taxpayers Union Foundation warns, "At a time when new entrepreneurship should be fostered, a wealth tax would do the opposite." Their concern is that such taxes would disincentivize business growth and innovation, as founders could face steep tax bills simply for owning successful companies.
For example, a business owner with a company valued at $100 million would owe $1.2 million annually under Sanders' plan, forcing them to sell part of their stake just to pay the tax. Over time, this could discourage the creation of transformative companies like Tesla or Apple. Critics fear that these measures would ultimately stifle the very kind of risk-taking that drives economic growth.
A report from TaxFoundation.org also warned that wealth taxes could lead to capital flight, pointing to countries like France and Germany that abandoned similar policies after they proved ineffective.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a>
The results have been messy even in nations where wealth taxes still exist, like Spain and Norway. Spain, for example, has seen marginal tax rates climb above 100% in some cases, discouraging investment and hurting wealth generation across all income levels.
Despite the pushback, Sanders is standing firm. In his speech at the Democratic National Convention in August, Sanders stated, &#8220;Brothers and sisters, bottom line, we need an economy that works for all of us … not just the billionaire class."
Whether you agree with him or not, his proposal forces a crucial question: Is it time to rethink <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">how wealth is distributed in America</a>? Or will the unintended consequences of such radical ideas outweigh their potential benefits?&nbsp;
Read Next:
<ul>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Bernie Sanders Proposes Taxing Income Over $1 Billion At 100% And Urges It's Time To Make 'Greedy Billionaires' Pay Their Fair Share

T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) has outperformed the market over the past 10 years by 13.19% on an annualized basis producing an average annual return of 24.51%. Currently, T-Mobile US has a market capitalization of $269.04 billion. 
Buying $1000 In TMUS: If an investor had bought $1000 of TMUS stock 10 years ago, it would be worth $9,240.64 today based on a price of $231.83 for TMUS at the time of writing.
<h3>T-Mobile US's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734132608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TMUS

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 11.52% on an annualized basis producing an average annual return of 22.84%. Currently, Apollo Global Management has a market capitalization of $99.83 billion. 
Buying $100 In APO: If an investor had bought $100 of APO stock 10 years ago, it would be worth $801.95 today based on a price of $176.43 for APO at the time of writing.
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734131721_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) has outperformed the market over the past 10 years by 18.06% on an annualized basis producing an average annual return of 29.38%. Currently, MSCI has a market capitalization of $48.99 billion. 
Buying $100 In MSCI: If an investor had bought $100 of MSCI stock 10 years ago, it would be worth $1,331.98 today based on a price of $625.10 for MSCI at the time of writing.
<h3>MSCI's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734130821_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MSCI

Here's How Much $100 Invested In MSCI 10 Years Ago Would Be Worth Today

CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) announced today that its Board of Trustees declared a quarterly dividend of $0.52 per common share for the period ending December 31, 2024. The dividend is payable on January 16, 2025 to common shareholders of record on January 2, 2025.&nbsp;&nbsp;

Dividends

CUBE

CubeSmart Increases Quarterly Common Dividend From $0.51 To $0.52 Per Share

Insight Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 10.59%. Currently, Insight Enterprises has a market capitalization of $5.18 billion. 
Buying $100 In NSIT: If an investor had bought $100 of NSIT stock 20 years ago, it would be worth $753.63 today based on a price of $158.94 for NSIT at the time of writing.
<h3>Insight Enterprises's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734129012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NSIT

Here's How Much You Would Have Made Owning Insight Enterprises Stock In The Last 20 Years

Trading Halt: Halted at 5:26:59 p.m. ET - Trading Halt: Halt News Pending

SPX Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) has outperformed the market over the past 5 years by 11.87% on an annualized basis producing an average annual return of 25.45%. Currently, SPX Techs has a market capitalization of $7.21 billion. 
Buying $1000 In SPXC: If an investor had bought $1000 of SPXC stock 5 years ago, it would be worth $3,074.32 today based on a price of $155.53 for SPXC at the time of writing.
<h3>SPX Techs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734128108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPXC

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Alpha Modus Holdings, Inc. ("Alpha Modus" or the "Company"), a technology company with a core focus on artificial intelligence in retail, is pleased to announce that the business combination between Insight Acquisition Corp. and Alpha Modus Corp. has closed, and Alpha Modus's common stock and warrants will begin trading on the Nasdaq Global Market under the ticker symbols "AMOD" and "AMODW", respectively, on Monday, December 16, 2024.
In connection with the closing of the business combination, the combined company consummated and issued a secured convertible promissory note to an investor, in exchange for net proceeds of approximately $2.6 million, which will be used primarily to cover transaction costs and for working capital. The structure of the financing does not include commitment or warrant shares and is structured with the potential for an additional $5 million capital infusion for working capital purposes in the future.

AMOD

INAQ

Alpha Modus And Insight Acquisition Corp Close Business Combination And Alpha Modus Will Begin Trading Under "AMOD" Ticker, December 16, 2024

NKTX

Nkarta 13G Filing Shows Citadel Advisors Reported A 5.4% Stake In The Co As Of December 6, 2024

Offerings

WATT

Energous Corp Files For Mixed Shelf Of Up To $80M

LKQ Corp Detects Unauthorized Access To It Systems In Canada; Canada Business Unit Operations Impacted For A Few Weeks Due To Cyber Incident; Business Unit In Canada Now Operating Near Full Capacity; Believes Cyber Incident Impacts Not Material To Financial Condition For FY

<figure class="table"> 
<table>
<tbody>
<tr>
<td> Termination of a Material Definitive Agreement</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
On January 7, 2022, Century Therapeutics, Inc. (the "Company") entered into a Research, Collaboration and License Agreement (the "Collaboration Agreement") with Bristol-Myers Squibb Company ("BMS") to collaborate on the research, development and commercialization of induced pluripotent stem cell derived, engineered natural killer cell and/or gamma delta T cell programs for hematologic malignancies.
&nbsp;
Following an internal corporate portfolio prioritization process, BMS notified the Company on December 12, 2024 that it would be terminating the Collaboration Agreement in its entirety without cause. The termination will be effective on March 12, 2025. The Company is encouraged by the scientific progress on the programs and will evaluate opportunities in acute myeloid leukemia and multiple myeloma in the context of the ongoing strategic review of Century's pre-clinical pipeline. Both parties will work together in accordance with the termination provisions of the Collaboration Agreement.

Biotech

Contracts

General

IPSC

Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma  In The Context Of The Ongoing Strategic Review Of Century's Pre-clinical Pipeline

Earnings

XCHG Q2 2024 EPS $(0.002) Down From $0.001 YoY; Revenue $9M Down From $12.20M  YoY

Insider Trades

Alaska Air Group CEO And President Benito Minicucci Sold 30,000 Shares At An Average Price Of $65.07/Share

TKO Group Files For Mixed Shelf; Size Not Disclosed

Amrep (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXR#NYSE">AXR</a>) reported quarterly earnings of $0.75 per share. This is a 257.14 percent increase over earnings of $0.21 per share from the same period last year. The company reported $11.91 million in sales this quarter. This is a 34.47 percent increase over sales of $8.85 million the same period last year.

Amrep Q2 EPS $0.75 Up From $0.21 YoY, Sales $11.91M Up From $8.85M YoY

What Happened: OpenAI has responded to Elon Musk's legal efforts to prevent its transition to a fully for-profit structure, accusing the billionaire of undermining the company after failing to gain control <a href="https://www.benzinga.com/topic/openai">during earlier negotiations.</a> 
In a recent blog post, OpenAI revealed that Musk had initially supported restructuring the organization into a for-profit entity in 2017 but abandoned the idea when his proposal to hold majority control was rejected. "[Musk] walked away and told us we would fail," OpenAI stated, <a href="https://www.cnbc.com/2024/12/13/openai-says-elon-musk-wanted-it-to-be-for-profit-in-2017.html">CNBC </a>reports.
The dispute stems from Musk's broader critique of OpenAI, which he co-founded, and its growing relationship with Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). Musk has filed for a court injunction, claiming the company's shift betrays its original nonprofit mission. 
Musk's complaints also allege that Microsoft benefits from restricted access to advanced AI models <a href="https://www.benzinga.com/24/12/42382569/elon-musk-asks-was-it-ever-not-a-lie-as-he-accuses-openai-of-selling-out-to-microsoft-and-betraying-its-founding-mission">while stifling competition.</a> He voiced concerns about monopolistic behavior in the industry, which have been central to his ongoing legal disputes with OpenAI and Microsoft.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42489039/feds-december-meeting-could-crush-rate-cut-optimism-for-2025">Fed&#8217;s December Meeting Could Crush Rate Cut Optimism For 2025</a>
OpenAI, however, maintains that the transformation aligns with its mission of advancing artificial intelligence responsibly, while remaining competitive in an evolving market.
Why It Matters: Musk's criticisms highlight growing tension within the AI industry as organizations navigate commercial pressures and ethical concerns. OpenAI has become a dominant force in generative AI, valued at $157 billion and attracting substantial investments, including $14 billion from Microsoft.
Musk, meanwhile, has positioned his own venture, xAI, as a rival, raising billions and launching its Grok chatbot. The unfolding legal battle underscores the high stakes in a sector expected to reach $1 trillion in revenue within a decade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42489019/teslas-76-post-trump-rally-bullish-run-or-signal-to-cash-out">Tesla&#8217;s 76% Post-Trump Rally: Bullish Run Or Signal To Cash Out?</a></li>
</ul>
Photo: Shutterstock

Legal

Tech

MSFT

TSLA

OpenAI Challenges Musk's Lawsuit, Reveals 2017 Profit Talks

Actuate Therapeutics shares rise 6% following $22.4M IPO

Actuate Therapeutics shares rise 6% following a $22.4M IPO

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

Actuate Therapeutics opened on Aug. 13 at $9.88. The biopharmaceutical company had priced its initial public offering of 2.8 million shares at a price of $8.00 per share.

Actuate Therapeutics Makes Public Debut

IPO Roundup: WeRide, Reitar Logtech and more

Pheton Holdings and Powell Max opened for trading on Thursday at $3.76 and $4.30, respectively. While the number of initial public offerings has rebounded from 2023, IPOs remain well below pre-pandemic levels.

Pheton, Powell Max Make Public Debut

Actuate Therapeutics (ACTU) announced that the U.S. Food and Drug Administration, FDA, has granted rare pediatric disease designation to elraglusib...

Actuate announces FDA rare pediatric disease designation to elraglusib

Actuate gets FDA rare pediatric disease designation for its bone cancer treatment

Actuate Therapeutics (ACTU) announced that the Company will be added to the Russell 2000 Index as part of the planned fourth quarter IPO additions ...

Actuate Therapeutics added to Russell 2000 Index

Actuate Therapeutics to join Russell 2000 index

ACTU

AVPT

BLIV

FACTU

FBGL

HCAI

HMHW

HOND

HONDU

LGCY

PMAX

PTHL

RITR

SBXD

SPAI

TDTH

TMGX

TOPP

TTCIF

VACH

WETH

IPOs

Press Releases

Actuate Therapeutics Announces Closing of Initial Public Offering

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Health Care

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Comments

Actuate Therapeutics

Actuate Therapeutics (ACTU) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL